Development of new anti-tuberculosis drug candidates.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Tohoku journal of experimental medicine

• Publication date

  2010-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1620/TJEM.221.97PMID 20467231
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance.

  2009cited by this paper
• Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects

  2009cited by this paper
• Once-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibility.

  2009cited by this paper
• The Diarylquinoline R207910 Is Bactericidal against Mycobacterium leprae in Mice at Low Dose and Administered Intermittently

  2009cited by this paper
• Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

  2009cited by this paper
• Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.

  2009cited by this paper
• A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.

  2009cited by this paper
• Assessment of the Effects of the Nitroimidazo-Oxazine PA-824 on Renal Function in Healthy Subjects

  2009cited by this paper
• Dry Powder Nitroimidazopyran Antibiotic PA-824 Aerosol for Inhalation

  2009cited by this paper
• Rates and Mechanisms of Resistance Development in Mycobacterium tuberculosis to a Novel Diarylquinoline ATP Synthase Inhibitor

  2009cited by this paper
• The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

  2009cited by this paper
• Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis.

  2008cited by this paper
• Selectivity of TMC207 towards Mycobacterial ATP Synthase Compared with That towards the Eukaryotic Homologue

  2008cited by this paper
• New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development

  2008cited by this paper
• Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis

  2008cited by this paper
• Provider-initiated HIV testing and counseling in TB clinical settings: tools for program implementation.

  2008cited by this paper
• PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release

  2008cited by this paper
• A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.

  2008cited by this paper
• Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis

  2008cited by this paper
• Impact of the Interaction of R207910 with Rifampin on the Treatment of Tuberculosis Studied in the Mouse Model

  2008cited by this paper
• Emerging drugs for active tuberculosis.

  2008cited by this paper
• Overview of anti-tuberculosis (TB) drugs and their resistance mechanisms.

  2007cited by this paper
• In Vitro-Selected Linezolid-Resistant Mycobacterium tuberculosis Mutants

  2007cited by this paper
• Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey.

  2007cited by this paper
• First Linezolid-Resistant Clinical Isolates of Mycobacterium tuberculosis

  2007cited by this paper
• In search of new cures for tuberculosis.

  2007cited by this paper
• Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs

  2007cited by this paper
• Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

  2007cited by this paper
• OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice

  2006cited by this paper
• Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

  2006cited by this paper
• Synergistic Activity of R207910 Combined with Pyrazinamide against Murine Tuberculosis

  2006cited by this paper
• Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases.

  2006cited by this paper
• Combination Chemotherapy with the Nitroimidazopyran PA-824 and First-Line Drugs in a Murine Model of Tuberculosis

  2006cited by this paper
• Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis: Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo Efficacy

  2006cited by this paper
• Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.

  2006cited by this paper
• New drug candidates and therapeutic targets for tuberculosis therapy.

  2006cited by this paper
• Moxifloxacin and Gatifloxacin in an Acid Model of Persistent Mycobacterium tuberculosis

  2006cited by this paper
• Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro.

  2006cited by this paper
• Mycobacterium leprae Is Naturally Resistant to PA-824

  2006cited by this paper
• Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis.

  2006cited by this paper
• Pharmacodynamics and pharmacokinetics of SQ109, a new diamine‐based antitubercular drug

  2005cited by this paper
• Novel fluoroquinolones: design, synthesis, and in vivo activity in mice against Mycobacterium tuberculosis H37Rv.

  2005cited by this paper
• Preclinical Testing of the Nitroimidazopyran PA-824 for Activity against Mycobacterium tuberculosis in a Series of In Vitro and In Vivo Models

  2005cited by this paper
• Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

  2005cited by this paper
• A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

  2005cited by this paper
• Bactericidal Action of Gatifloxacin, Rifampin, and Isoniazid on Logarithmic- and Stationary-Phase Cultures of Mycobacterium tuberculosis

  2005cited by this paper
• Linezolid for the treatment of multidrug-resistant tuberculosis.

  2005cited by this paper
• Bactericidal Activity of the Nitroimidazopyran PA-824 in a Murine Model of Tuberculosis

  2005cited by this paper
• Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines.

  2005cited by this paper
• Persistent and dormant tubercle bacilli and latent tuberculosis.

  2004cited by this paper
• Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study

  2004cited by this paper
• In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis That Are Susceptible or Resistant to First-Line Antituberculous Drugs

  2003cited by this paper
• Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis

  2003cited by this paper
• Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.

  2003cited by this paper
• Bactericidal Activity of Increasing Daily and Weekly Doses of Moxifloxacin in Murine Tuberculosis

  2002cited by this paper
• In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.

  2002cited by this paper
• A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

  2000cited by this paper
• In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis

  1993cited by this paper

• Isoniazid Analogs and Their Biological Activities as Antitubercular Agents (A Review)

  2024cites this paper
• Design, synthesis and biological studies of some new imidazole-1,2,3-triazole hybrid derivatives

  2022cites this paper
• An analysis of the upstream supply chain for second-line drugs for multidrug-resistant tuberculosis

  2017cites this paper
• A SHORT REVIEWON DRUG RESISTANCE AND COMPLICATIONSIN THERAPYOF TUBERCULOSIS

  2016cites this paper
• Tuberculosis therapy for 2016 and beyond

  2016cites this paper
• Therapeutic Targets and Rational Drug Designing for Antitubercular Drugs

  2016cites this paper
• Protective Effects of CAPE on Isoniazid and Rifampicin Induced Hepatic and Pancreatic Injury

  2016influential citation
• Development of Antituber- cular Agents: Potential for β-lactum Based

  2015cites this paper
• Mini review on diarylquinolone compound Bedaquiline and some other quinolone derivatives and their antitubercular activity

  2015cites this paper
• A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis

  2015cites this paper
• Green synthesis and in silico investigation of dihydro-2H-benzo[1,3]oxazine derivatives as inhibitors of Mycobacterium tuberculosis

  2015cites this paper
• Study of Some Analogue of Currently Cilinically used Pyrazinamide Compounds

  2015cites this paper
• Mini Review Study of Antitubercular Drugs of Nicotinamide, Thioisonicotinamide and Pyrazinamide Derivatives

  2014cites this paper
• Antitubercular drugs: Advances in nitrogen containing heterocyclic compounds and some other derivatives

  2014cites this paper
• Fluorinated compounds against Mycobacterium tuberculosis.

  2013cites this paper
• The protective effects of caffeic acid phenethyl ester in isoniazid and ethambutol-induced ocular toxicity of rats

  2013cites this paper
• 2D & 3D QSAR STUDIES OF BIARYL ANALOGUES OF PA-824 HAVING VARIOUS ETHER LINKERS: AN APPROACH TO DESIGN ANTITUBERCULAR AGENTS

  2013cites this paper
• Safety and Efficacy of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB)

  2013cites this paper
• Synthesis and Evaluation of 2-Amino-4H-Pyran-3-Carbonitrile Derivatives as Antitubercular Agents

  2013cites this paper
• A REVIEW ON POTENT ANTITUBERCULAR AGENT ISONIAZID AND ITS ANALOGUES

  2013cites this paper
• Colloidal carriers: a rising tool for therapy of tuberculosis.

  2012cites this paper
• Recent Advances in the Research of Heterocyclic Compounds as Antitubercular Agents

  2012cites this paper
• Kinetic Template‐Guided Tethering of Fragments

  2012cites this paper
• Astraodoric acids A-D: new lanostane triterpenes from edible mushroom Astraeus odoratus and their anti-Mycobacterium tuberculosis H37Ra and cytotoxic activity.

  2012cites this paper
• Mycobacterium tuberculosis mutants with multidrug resistance: History of origin, genetic and molecular mechanisms of resistance, and emerging challenges

  2012cites this paper
• Novel polycyclic 'cage'-1,2-diamines as potential anti-tuberculosis agents.

  2012cites this paper
• New treatment options for multidrug-resistant tuberculosis

  2012influential citation
• 9 Antitubercular Drugs Development : Recent Advances in Selected Therapeutic Targets and Rational Drug Design

  2012cites this paper
• Antituberculosis therapy for 2012 and beyond

  2012cites this paper
• Novel Linear Diamine Disubstituted Polycyclic ‘Cage’ Derivatives as Potential Antimycobacterial Candidates

  2011cites this paper
• New tuberculosis drugs on the horizon.

  2011cites this paper
• Tuberculosis drugs: new candidates and how to find more.

  2011cites this paper
• Local Microbiologies of Tuberculosis: Insights from the Republic of Georgia

  2011cites this paper
• Liposomes as drug delivery systems for the treatment of TB.

  2011cites this paper
• Antitubercular Drugs Development: Recent Advances in Selected Therapeutic Targets and Rational Drug Design

  2011cites this paper
• Synthesis and Structure−Activity Relationships of Aza- and Diazabiphenyl Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)

  2010cites this paper